Want to see HK:7666 full AI Analyst Report?
Top Page
Metis TechBio Co., Ltd. Class H
(7666)
Select Model
Select Model
Rating:58Neutral
Price Target:
$18.50
Action:Reiterated
Date:09/09/26
The score is driven primarily by improving financial trajectory and balance sheet repair (stronger revenue/gross margin and sharply reduced leverage), but it is capped by continued large losses and ongoing negative operating/free cash flow. Technicals are supportive with price above key moving averages and positive momentum, while valuation remains challenged due to negative earnings and no dividend data.
Positive Factors
Revenue rebound
The sharp 2025 revenue rebound indicates stronger commercial traction and improved demand relative to the prior year. If sustained, higher scale can support broader operating leverage, strengthen the company’s market position, and provide a larger base for future product investment.
Negative Factors
Severe operating losses
Despite better revenue and gross margin, the company remains far from operating breakeven, with EBIT and EBITDA losses several times revenue. This indicates that the cost structure is still consuming the benefits of improved gross profitability and may require substantial execution before earnings stabilize.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
The sharp 2025 revenue rebound indicates stronger commercial traction and improved demand relative to the prior year. If sustained, higher scale can support broader operating leverage, strengthen the company’s market position, and provide a larger base for future product investment.
Read all positive factors
Metis TechBio Co., Ltd. Class H (7666) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$18.23B
Dividend YieldN/A
Average Volume (3M)2.99M
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees150
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,083,110,100
10 Day Avg. Volume2,685,321
30 Day Avg. Volume2,993,916
Financial Highlights & Ratios
PEG Ratio3.01
Price to Book (P/B)24.28
Price to Sales (P/S)247.19
P/FCF Ratio-185.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$18.71Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Metis TechBio Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Metis TechBio Co., Ltd., founded in 2020 and headquartered in Beijing, China, (previously Hangzhou Jitai Pharmaceutical Technology Co., Ltd.) specializes in the advanced research and development of AI-powered nanomaterials. The company's core miss...
Metis TechBio Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
46
Neutral
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 14.63M | 206.76K | 1.32M |
| Gross Profit | 9.66M | -4.66M | -4.52M |
| EBITDA | -45.40M | -41.34M | -67.03M |
| Net Income | -54.59M | -69.65M | -82.32M |
Balance Sheet | |||
| Total Assets | 184.61M | 143.59M | 185.12M |
| Cash, Cash Equivalents and Short-Term Investments | 161.04M | 107.94M | 118.55M |
| Total Debt | 18.76M | 320.89M | 310.42M |
| Total Liabilities | 34.96M | 332.26M | 317.58M |
| Stockholders Equity | 148.93M | -189.31M | -137.79M |
Cash Flow | |||
| Free Cash Flow | -19.54M | -33.84M | -34.22M |
| Operating Cash Flow | -16.94M | -33.37M | -27.22M |
| Investing Cash Flow | 4.89M | 11.01M | -57.28M |
| Financing Cash Flow | 51.48M | 19.99M | 113.16M |
Metis TechBio Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$25.77B | 62.16 | 15.79% | ― | 48.04% | 166.72% | |
58 Neutral | HK$18.23B | -48.50 | 270.37% | ― | ― | ― | |
52 Neutral | HK$22.80B | -14.63 | -27.40% | ― | 5.38% | 16.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$8.38B | -41.37 | -10.27% | ― | -31.77% | -177.01% | |
44 Neutral | HK$7.88B | -71.44 | -9.49% | ― | 68.12% | 81.84% | |
44 Neutral | HK$17.66B | -7.56 | -179.83% | ― | 385.38% | ― |
* Healthcare Sector Average
HK:7666
Metis TechBio Co., Ltd. Class H
17.57
-6.23
-26.18%
HK:9688
Zai Lab Ltd
20.00
-4.68
-18.96%
HK:9966
Alphamab Oncology
8.31
-2.26
-21.38%
HK:2171
CARsgen Therapeutics Holdings Ltd.
13.40
-8.80
-39.64%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
61.75
36.19
141.59%
HK:2493
Mabwell (Shanghai) Bioscience Co., Ltd. Class H
20.84
-6.96
-25.04%
Metis TechBio Co., Ltd. Class H Corporate Events
Metis TechBio Narrows Losses as Biological AI Strategy Gains Momentum
Aug 25, 2026
Metis TechBio Co., Ltd. reported unaudited interim results for the first half of 2026, posting operating revenue of RMB154.3 million, a sharp increase from a low base a year earlier, and holding RMB3,025.3 million in cash, deposits and marketable ...
Metis TechBio to Join Hang Seng Composite Index, Eyes Broader Investor Base
Aug 23, 2026
Metis TechBio Co., Ltd., a Hong Kong-listed joint stock company from the Chinese mainland, trades its H shares on the Main Board of the Stock Exchange of Hong Kong. Its listing gives the company exposure to both Hong Kong and mainland investors th...
Metis TechBio Sets August Board Meeting to Review Interim Results and Dividend
Aug 12, 2026
Metis TechBio Co., Ltd. has scheduled a board meeting for August 25, 2026 to review and approve the unaudited interim results for the six months ended June 30, 2026. The board will also consider the declaration of an interim dividend and attend to...
Metis TechBio Strengthens Governance With New Joint Company Secretary and HKEX Waiver
Aug 4, 2026
Metis TechBio Co., Ltd. has appointed Nan Cao as joint company secretary effective 4 August 2026, alongside existing joint company secretary Hei Chan, in a move that strengthens its legal and governance capabilities. Cao brings a legal background ...
Metis TechBio to Deploy AI Formulation Platform at Hengrui Pharmaceuticals
Aug 3, 2026
Metis TechBio Co., Ltd., a Hong Kong-listed AI drug delivery specialist, has built its business around NanoForge, an AI-driven nano-delivery platform backed by the world’s largest proprietary lipid nanoparticle library. Leveraging this infra...
Metis TechBio Reshapes Finance and Governance Team After Hong Kong Listing
Jul 31, 2026
Metis TechBio Co., Ltd. announced that chief financial officer, board secretary, joint company secretary and Hong Kong process agent Dr. Chong Fu will step down from these roles effective August 1, 2026, transitioning to an advisory position focus...
Metis TechBio seals up to US$1.6 billion TCE licensing deal with Deerfield-backed Boulevard Bio
Jun 30, 2026
Metis TechBio has signed a global exclusive licensing agreement with Boulevard Bio, a Deerfield-backed U.S. biotech, for its proprietary trispecific T cell engager MTS-128. The deal grants Boulevard Bio worldwide rights to develop, manufacture and...
Metis TechBio reshapes company secretariat and maintains listing-rule waiver
Jun 12, 2026
Metis TechBio has reshuffled its governance team, announcing the resignation of joint company secretary and authorized representative Ms. Cheng Yuk Ting and the appointment of Tricor Services veteran Ms. Chan Hei to both roles, effective June 12, ...
Metis TechBio Updates Articles After Full Exercise of H-Share Over-Allotment
Jun 10, 2026
Metis TechBio Co., Ltd. has updated its articles of association to reflect changes in share capital and structure following the full exercise of an over-allotment option in its Hong Kong listing. The company issued an additional 30,184,000 H share...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.